278 related articles for article (PubMed ID: 29773068)
21. CD47/SIRPα blocking enhances CD19/CD3-bispecific T cell engager antibody-mediated lysis of B cell malignancies.
Xu L; Wang S; Li J; Li B
Biochem Biophys Res Commun; 2019 Feb; 509(3):739-745. PubMed ID: 30611570
[TBL] [Abstract][Full Text] [Related]
22. A phase 1b study of blinatumomab in Japanese children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Horibe K; Morris JD; Tuglus CA; Dos Santos C; Kalabus J; Anderson A; Goto H; Ogawa C
Int J Hematol; 2020 Aug; 112(2):223-233. PubMed ID: 32564243
[TBL] [Abstract][Full Text] [Related]
23. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma.
Viardot A; Goebeler ME; Hess G; Neumann S; Pfreundschuh M; Adrian N; Zettl F; Libicher M; Sayehli C; Stieglmaier J; Zhang A; Nagorsen D; Bargou RC
Blood; 2016 Mar; 127(11):1410-6. PubMed ID: 26755709
[TBL] [Abstract][Full Text] [Related]
24. Exposure-response analysis of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukaemia and comparison with standard of care chemotherapy.
Kuchimanchi M; Zhu M; Clements JD; Doshi S
Br J Clin Pharmacol; 2019 Apr; 85(4):807-817. PubMed ID: 30645768
[TBL] [Abstract][Full Text] [Related]
25. Safety of AFM11 in the treatment of patients with B-cell malignancies: findings from two phase 1 studies.
Topp M; Dlugosz-Danecka M; Skotnicki AB; Salogub G; Viardot A; Klein AK; Hess G; Michel CS; Grosicki S; Gural A; Schwarz SE; Pietzko K; Gärtner U; Strassz A; Alland L; Mayer J
Trials; 2023 Jan; 24(1):4. PubMed ID: 36597128
[TBL] [Abstract][Full Text] [Related]
26. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.
Klinger M; Brandl C; Zugmaier G; Hijazi Y; Bargou RC; Topp MS; Gökbuget N; Neumann S; Goebeler M; Viardot A; Stelljes M; Brüggemann M; Hoelzer D; Degenhard E; Nagorsen D; Baeuerle PA; Wolf A; Kufer P
Blood; 2012 Jun; 119(26):6226-33. PubMed ID: 22592608
[TBL] [Abstract][Full Text] [Related]
27. Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Coyle L; Morley NJ; Rambaldi A; Mason KD; Verhoef G; Furness CL; Zhang A; Jung AS; Cohan D; Franklin JL
Leuk Lymphoma; 2020 Sep; 61(9):2103-2112. PubMed ID: 32546071
[TBL] [Abstract][Full Text] [Related]
28. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
Topp MS; Kufer P; Gökbuget N; Goebeler M; Klinger M; Neumann S; Horst HA; Raff T; Viardot A; Schmid M; Stelljes M; Schaich M; Degenhard E; Köhne-Volland R; Brüggemann M; Ottmann O; Pfeifer H; Burmeister T; Nagorsen D; Schmidt M; Lutterbuese R; Reinhardt C; Baeuerle PA; Kneba M; Einsele H; Riethmüller G; Hoelzer D; Zugmaier G; Bargou RC
J Clin Oncol; 2011 Jun; 29(18):2493-8. PubMed ID: 21576633
[TBL] [Abstract][Full Text] [Related]
29. Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment.
Bock AM; Nowakowski GS; Wang Y
Curr Treat Options Oncol; 2022 Feb; 23(2):155-170. PubMed ID: 35182296
[TBL] [Abstract][Full Text] [Related]
30. Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL.
Nägele V; Kratzer A; Zugmaier G; Holland C; Hijazi Y; Topp MS; Gökbuget N; Baeuerle PA; Kufer P; Wolf A; Klinger M
Exp Hematol Oncol; 2017; 6():14. PubMed ID: 28533941
[TBL] [Abstract][Full Text] [Related]
31. Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignancies.
Zugmaier G; Klinger M; Schmidt M; Subklewe M
Mol Immunol; 2015 Oct; 67(2 Pt A):58-66. PubMed ID: 25883042
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia.
Ribera JM
Expert Rev Hematol; 2017 Dec; 10(12):1057-1067. PubMed ID: 29082835
[TBL] [Abstract][Full Text] [Related]
33. Blinatumomab: Bridging the Gap in Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.
Folan SA; Rexwinkle A; Autry J; Bryan JC
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S2-5. PubMed ID: 27521320
[TBL] [Abstract][Full Text] [Related]
34. Blinatumomab: A novel, bispecific, T-cell engaging antibody.
May MB; Glode A
Am J Health Syst Pharm; 2016 Jan; 73(1):e6-e13. PubMed ID: 26683683
[TBL] [Abstract][Full Text] [Related]
35. Blinatumomab for the treatment of acute lymphoblastic leukemia.
Kaplan JB; Grischenko M; Giles FJ
Invest New Drugs; 2015 Dec; 33(6):1271-9. PubMed ID: 26383529
[TBL] [Abstract][Full Text] [Related]
36. Harnessing T cells to fight cancer with BiTE® antibody constructs--past developments and future directions.
Klinger M; Benjamin J; Kischel R; Stienen S; Zugmaier G
Immunol Rev; 2016 Mar; 270(1):193-208. PubMed ID: 26864113
[TBL] [Abstract][Full Text] [Related]
37. A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Ribrag V; Dupuis J; Tilly H; Morschhauser F; Laine F; Houot R; Haioun C; Copie C; Varga A; Lambert J; Hatteville L; Ziti-Ljajic S; Caron A; Payrard S; Coiffier B
Clin Cancer Res; 2014 Jan; 20(1):213-20. PubMed ID: 24132920
[TBL] [Abstract][Full Text] [Related]
38. Adhesion of T Cells to Endothelial Cells Facilitates Blinatumomab-Associated Neurologic Adverse Events.
Klinger M; Zugmaier G; Nägele V; Goebeler ME; Brandl C; Stelljes M; Lassmann H; von Stackelberg A; Bargou RC; Kufer P
Cancer Res; 2020 Jan; 80(1):91-101. PubMed ID: 31662326
[TBL] [Abstract][Full Text] [Related]
39. Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors.
Stein AS; Schiller G; Benjamin R; Jia C; Zhang A; Zhu M; Zimmerman Z; Topp MS
Ann Hematol; 2019 Jan; 98(1):159-167. PubMed ID: 30238148
[TBL] [Abstract][Full Text] [Related]
40. Blinatumomab: a novel therapy for the treatment of non-Hodgkin's lymphoma.
Bukhari A; Lee ST
Expert Rev Hematol; 2019 Nov; 12(11):909-918. PubMed ID: 31583919
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]